An estimated 234,000 new cases of prostate cancer will be diagnosed in the United States this year, making it one of the most common cancers affecting American men; however, it can be a controversial disease to diagnose and treat now that there is research abounding for both “watchful waiting and aggressive treatments. Dr. Oh supplies balanced information, with articles on: Prostate Cancer: To Screen or Not To Screen?; High Intensity Focused Ultrasound: Ready for Primetime?; The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy; Primary and Salvage Prostate Cancer Cryotherapy; and The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy, to name a few. The state-of-the art information presented in this issue make is must-have for all urologists.

This thoroughly updated and revised edition of a widely acclaimed book provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. The authors explain the trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting, and hereditary prostate cancer. Additional chapters reflect progress in the management of locally advanced disease, the use of nomograms to predict outcomes, the medical management of erectile dysfunction, brachytherapy, and deciding between surgery and radiation. A compact disk accompanies the book for downloading the book to a PC or PDA.

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.

Winner of the Council Chair's Choice Award at the 2019 British Medical Association Awards. Cancer Prevention and Screening offers physicians and all clinical healthcare professionals a comprehensive, useful source of the latest information on cancer screening and prevention with both a global and a multidisciplinary perspective. Includes background information on epidemiology, cancer prevention, and cancer screening, for quick reference Offers the latest information for clinical application of the most recent techniques in prevention and screening of all major and many lesser cancer types Emphasises the importance of multidisciplinary teamwork in cancer screening Highlights frequent dilemmas and difficulties encountered during cancer screening Provides clear-cut clinical strategies for optimal patient education, communication, and compliance with cancer prevention techniques

This book addresses key issues of controversy in radiation oncology for each disease site, with expert commentaries from leading authorities in the field. It identifies areas of confusion arising from discrepant data in the literature regarding certain clinical scenarios for different diseases and presents high-level evidence on each issue with a view to fostering best practice. Controversies in Radiation Oncology will serve as a very useful resource for busy radiation oncology physicians, practitioners, and trainees/residents/fellows seeking to utilize evidence in the literature to guide the management of radiation therapy patients.

Reveals how fear-based and inaccurate testing is resulting in unnecessary high-risk surgeries, arguing that the PSA test was never intended for prostate cancer screening.

Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, reviews new, valuable approaches to the treatment of prostate cancer in men. The latest edition contains new material on molecular imaging, new treatments for prostate cancer, molecular targets, cell signaling pathways, bioinformatics, and pathogenomics. The book details the latest innovations and advances in prostate cancer and may be used as a rapid reference text for readers. The volume profiles the latest advances in cancer research and treatment and includes profound studies in prostate stem cells, cancer-host interactions, hedgehog signaling in development and cancer, cholesterol and cell signaling, gene therapy for advanced prostate cancer, and noninvasive strategies such as molecular imaging to visualize gene expression. This new edition also investigates expression profiling and somatic alterations in prostate cancer progression and linkage studies of prostate cancer families to identify susceptibility genes. The issues of racial differences in prostate cancer mortality, radiotherapy for the treatment of locally advanced prostate cancer, recombinant antibody candidates for treatment, taxane-based chemotherapy, lethal phenotypes, and novel and efficient translation clinical trials are also presented in great depth. Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, provides readers with a general reference for prostate cancer from prevention to therapy and will be of value to clinicians, scientists, and administrators who strive to solve the cancer problem.